AstraZeneca's CEO Pascal Soriot warns the company must innovate at 'Chinese speed' to compete with emerging pharmaceutical rivals, citing the automotive industry's loss to Chinese electric vehicle dominance. Despite confidence in hitting $80bn 2030 sales targets, Soriot acknowledges the threat from Chinese innovators in novel drug technologies.
Participants at SPIEF-2026 believe Russia can succeed in the global pharmaceutical market by integrating AI, modern tech platforms, and regulatory/financial support. A key challenge identified is creating guaranteed demand for new drugs to attract investment.
A quarter featuring multiple eye-popping deals is no longer unusual for China’s pharmaceutical industry – in fact, it may soon be considered a slow season. In recent months, companies including CSPC Pharmaceutical and RemeGen have struck out-licensing agreements worth up to US$18.5 billion and US$5.6 billion respectively, while Haisco Pharmaceutical Group has added two of its own — most recently a deal worth up to US$745 million. Under the terms of the deal, the Beijing-based Haisco granted US...
